CING Share Price Performance
US$5.76
1.74 (43.28%)
Price US$5.76
Share Pricen/a
Cingulate Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
CING Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Cingulate Inc. Key Details
About CING
- Founded
- 2012
- Employees
- 14
- CEO
- WebsiteView website
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
